title: Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease.
abstract: 'Statins', drugs that lower cholesterol are widely used. Statins block cholesterol in the body and brain by inhibiting HMG-Co-A reductase. This pathway is shared by CoQ-10. An unintended consequence of the statins is lowering of CoQ-10. As CoQ-10 may play a role in PD, its possible statins may worsen PD. Such a report has appeared. Statins came into wide use in 1997-1998, 6 years before our study began. Thus 74% of our patients on a statin had a PD duration of 1-6 years versus 56% of our patients not on a statin. A direct comparison of patients on a statin and not on a statin would bias the study in favor of the statins: patients on a statin would have a shorter disease duration and less advanced PD. Therefore we divided the patients into two groups. Group I consisted of 128 patients on a statin, and 252 not on a statin who had PD for 1-6 years. In this group, disease severity (Hoehn & Yahr Stage), levodopa dose, Co-enzyme Q10 use, prevalence of 'wearing off', dyskinesia and dementia were similar. Group II consisted of 45 patients on a statin and 200 patients not on a statin who had PD for 7-22 years. In this group disease severity, levodopa dose, Co-enzyme Q10 use, prevalence of wearing off, dyskinesia and dementia were similar. Statins although they may affect Co-enzyme Q10 levels in the body and the brain, do not worsen PD at least as assessed by stage, and prevalence of wearing-off, dyskinesia, and dementia.
authors.affiliation: Department of Neurology, University of Miami School of Medicine, Miami, FL 33136, USA. al@parkinson.org
authors.forename: Abraham
authors.initials: A
authors.lastname: Lieberman
authors.forename: Kelly
authors.initials: K
authors.lastname: Lyons
authors.forename: Jay
authors.initials: J
authors.lastname: Levine
authors.forename: Robert
authors.initials: R
authors.lastname: Myerburg
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage; D002784:Cholesterol / Q000378:metabolism*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006949:Hyperlipidemias / Q000188:drug therapy*; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D012720:Severity of Illness Index; D014451:Ubiquinone / Q000378:metabolism*
chemical_list: D000978:Antiparkinson Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014451:Ubiquinone; D007980:Levodopa; D002784:Cholesterol